Friday, May 15, 2015
U.S. FDA warns on newer class of type 2 diabetes drugs
(Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could requireRead more...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment